We studied the effect of (2‐butyl‐4‐chloro‐1[[2'‐(1H‐tetrazol‐5‐yl) [1,1'‐biphenyl]methyl]‐1H‐imadazole‐5‐carboxylic acid,‐1‐ (ethoxycarbonyloxy) ethyl‐ester (HN‐65021), on angiotensin II induced vasoconstriction in forearm vasculature of eight healthy men. Placebo and HN‐65021 (5, 10 and 100 mg) were administered orally. Forearm blood flow was measured by venous occlusion plethysmography during rising dose brachial artery infusions of angiotensin II (0.3‐1000 pmol min‐1) 2 h after dosing. HN‐65021 inhibited angiotensin II, causing a shift to the right of the dose‐response curve. Angiotensin II (100 pmol min‐1) decreased mean blood flow in the infused arm by 63.1 +/‐ 3.2% when infused following placebo and by 49.9 +/‐ 4.3%, 50.7 +/‐ 3.5% and 36.4 +/‐ 2.8% following HN‐65021 doses of 5.10 and 100 mg respectively. These results demonstrate that HN‐65021 antagonises angiotensin II receptor mediated vasoconstriction in human forearm resistance vessels.
|Number of pages||3|
|Journal||British Journal of Clinical Pharmacology|
|Publication status||Published - 1995|